

**COVID-19 ANTIBODY TEST KITS – RECEIPT OF PRODUCT AUTHORISATION GRANTED BY
KEMENTERIAN KESEHATAN REPUBLIK INDONESIA**

The board of directors (the "**Board**") of Biolidics Limited (the "**Company**") and together with its subsidiaries, the "**Group**") refers to the announcement made on 26 April 2020 in relation to the Company's responses to the questions received from shareholders and the Securities Investors Association (Singapore) (SIAS) prior to the Company's annual general meeting and extraordinary general meeting held on 30 April 2020 (the "**Announcement**"). Specifically, the Company refers to its response to Question 1 of the Announcement in relation to its application with the Indonesian authorities for the use of the Company's test kits for the detection of Novel Coronavirus 2019 antibodies (the "**COVID-19 Antibody Test Kits**") in Indonesia.

Further to the Announcement, the Board wishes to update that the Company's COVID-19 Antibody Test Kits, had on 25 November 2020, obtained the relevant authorisation from Kementerian Kesehatan Republik Indonesia, which is the Ministry of Health in Indonesia, for it to be distributed and used in Indonesia (the "**Authorisation**"). The Authorisation remains valid until 25 November 2021 and the extension of its validity may be permissible should there be no undesirable events upon usage.

The receipt of the Authorisation is not expected to have any material impact on the net tangible assets or earnings per share of the Group for the current financial year ending 31 December 2020.

Save for their respective shareholdings in the Company (if any), the Company is not aware of any of its directors or substantial shareholders having any interest, direct or indirect, in the Authorisation.

For the avoidance of doubt, the results from the COVID-19 Antibody Test Kits are not to be used for confirmatory testing or as sole basis for diagnosis. The results will have to be interpreted together with clinical presentation and are to be confirmed with supplementary testing. In addition, shareholders and potential investors should note that policies in relation to diagnosis and/or detection of the COVID-19 virus and/or antibodies in various jurisdictions may change in response to developments in the COVID-19 situation, which is evolving rapidly. Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers if they are in doubt about the actions that they should take.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Non-Executive Non-Independent Chairman
26 November 2020

*This announcement has been prepared by the Company and has been reviewed by United Overseas Bank Limited (the "**Sponsor**") for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalyst. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr. Lim Hoon Khia, Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*